Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non–muscle invasive bladder cancer

Autor: Rossana Critelli, H. Barton Grossman, Tilman Todenhöfer, Wassim Kassouf, Bas W.G. van Rhijn, Molly A. Ingersoll, John A. Taylor, Antonia Vlahou, Marta Sanchez-Carbayo, Joan Palou, Mĺiss A. Hudson, Ashish Chandra, Thomas Behrens, Ashish M. Kamat, Bernd J. Schmitz-Dräger, Beate Pesch

Publikováno v: Urologic Oncology: Seminars and Original Investigations
Urologic Oncology: Seminars and Original Investigations, Elsevier, 2014, 32 (7), pp.1061-1068. ⟨10.1016/j.urolonc.2013.10.010⟩
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Urologic Oncology: Seminars and Original Investigations, 2014, 32 (7), pp.1061-1068. ⟨10.1016/j.urolonc.2013.10.010⟩

Objectives: Many molecular assays for bladder cancer diagnosis and surveillance have been developed over the past several decades. However, none of these markers have been routinely implemented into clinical decision making. Beyond their potential fo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a6a2bd9bacb4a7081dd282420b77be7
https://hal-pasteur.archives-ouvertes.fr/pasteur-01381004